Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-54912

ABSTRACT: Vascular histone deacetylation by pharmacological HDAC inhibition [SAHA, RNA-seq]

OTHER RELATED OMICS DATASETS IN: PRJNA159809PRJNA238014PRJNA159705PRJNA159807PRJNA238012PRJNA238016PRJNA238015

PROVIDER: E-GEOD-54912 | ExpressionAtlas | 2019-05-14

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-54912-analysis-methods.tsv	Tabular
	E-GEOD-54912-analytics.tsv	Tabular
	E-GEOD-54912-analytics.tsv.undecorated	Tabular
	E-GEOD-54912-analytics.tsv.undecorated.unrounded	Tabular
	E-GEOD-54912-analytics.tsv.unrounded	Tabular

Items per page:

1 - 5 of 33

Similar Datasets

Homo sapiens

Project description:Vascular histone deacetylation by pharmacological HDAC inhibition [TSA, RNA-seq]

| PRJNA159807 | ENA

Homo sapiens

Project description:Vascular histone deacetylation by pharmacological HDAC inhibition [SAHA, RNA-seq]

| PRJNA238012 | ENA

Homo sapiens

Project description:Vascular histone deacetylation by pharmacological HDAC inhibition [TSA, MBD-seq]

| PRJNA238014 | ENA

Homo sapiens

Project description:Vascular histone deacetylation by pharmacological HDAC inhibition [TSA, ChIP-seq]

| PRJNA159809 | ENA

Homo sapiens

Project description:Vascular histone deacetylation by pharmacological HDAC inhibition [SAHA, ChIP-seq]

| PRJNA238015 | ENA

Vascular histone deacetylation by pharmacological HDAC inhibition

Project description:Vascular histone deacetylation by pharmacological HDAC inhibition

| PRJNA159705 | ENA

Mus musculus

Project description:Vascular histone deacetylation by pharmacological HDAC inhibition [TSA, mouse, ChIP-seq]

| PRJNA238016 | ENA

Transcription profiling of human hepatocytes treated with doxorubicin and Trovafloxacin, super-series of E-GEOD-11940 and E-GEOD-11941

Project description:This SuperSeries is composed of the following subset Series:; GSE11940: Topoisomerase II inhibition involves characteristic chromosomal expression patterns: Doxorubicin study; GSE11941: Topoisomerase II inhibition involves characteristic chromosomal expression patterns: Trovafloxacin study Experiment Overall Design: Refer to individual Series

2008-10-26 | E-GEOD-11942 | biostudies-arrayexpress

RNA Seq Transcriptomic profiling of PDGF-stimulated primary human aortic smooth muscle cells treated with ORAI1 inhibitor relative to controls

Project description:Platelet-derived growth factor (PDGF) signalling and the subsequent activation of the calcium ion channel, ORAI1 are critical drivers of pathological remodelling of native vascular smooth muscle cells to proliferative state, which is a process associated with various vascular diseases. This study aims to reveal transcriptional networks altered following ORAI1 inhibition in vascular smooth muscle cells. To study the effect of ORAI1 inhibition on VSMC biology, we performed RNA-Seq analysis of PDGF-stimulated primary human aortic smooth muscle cells treated with either ORAI1 inhibitor, (n=4) or with vehicle (n=4), and investigated the effect of ORAI1 inhibition on the transcriptional response of cells.

2023-09-21 | E-MTAB-10955 | biostudies-arrayexpress

Vascular histone deacetylation by pharmacological HDAC inhibition [TSA, ChIP-seq]

Project description:HDAC inhibitors are thought to regulate gene expression by post-translational modification of histone as well as non-histone proteins. Often studied at single loci, increased histone acetylation is the paradigmatic mechanism of action, however, little is known of the extent of genome-wide changes of the mammalian genome when stimulated by the hydroxamic acids, TSA and SAHA. In primary human vascular endothelial cells we map the chromatin modifications, histone H3 acetylation of lysine 9 and 14 (H3K9/14ac) using chromatin immunoprecipitation (ChIP) coupled with massive parallel sequencing (ChIP-seq). Since acetylation mediated gene expression is often associated with modification of other lysine residues we also examined H3K4me3 and H3K9me3 as well as changes in CpG methylation (CpG-seq). Genome-wide mRNA sequencing indicates the differential expression of about 30% of genes, with almost equal numbers being up- and down- regulated. We observe deacetylation conferred by TSA and SAHA that are associated with decreased gene expression. Histone deacetylation is associated with the loss of p300/CBP binding at gene promoters. This study provides an important framework for HDAC inhibitor function in vascular biology and a comprehensive description of genome-wide deacetylation. HAEC ChIP-seq profiles for 3 histone marks of TSA treated and control samples were generated by deep sequencing, in triplicate, using Illumina GAIIx.

2014-02-23 | E-GEOD-37377 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data